Cutaneous malignancy after biologic therapy for inflammatory disease: An active comparator, retrospective cohort study - 19/08/25
Abstract |
Background |
The role biologics play in skin cancer among patients with inflammatory disease (ID) is uncertain. Skin cancer risk in patients with ID is elevated regardless of therapy, and there is a paucity of longitudinal data evaluating biologics that accounts for these ID-related confounders.
Objective |
To assess the risk of cutaneous malignancy after biologic therapy for ID using head-to-head comparisons to control confounding risks of ID.
Methods |
Data from 1,759,200 patients (2004-2024) with psoriasis, rheumatoid arthritis, and inflammatory bowel disease in the TriNetX network were analyzed. The risk of cutaneous malignancy was calculated after exposure to biologic therapy. Propensity score matching was implemented to control for confounders.
Results |
A total of 212,632 (12.1%) patients were prescribed biologics for ID. Risk analysis demonstrated a small but significant elevation in absolute risk of nonmelanoma skin cancer driven predominately by patients exposed to tumor necrosis factor inhibitors. No other agents analyzed individually demonstrated significant risk elevations.
Limitations |
Limitations include a retrospective approach and inherent errors/underreporting in electronic medical records.
Conclusion |
This study confirms the association of tumor necrosis factor inhibitors with nonmelanoma skin cancer. Other biologics including interleukin and Janus kinase inhibitors may contribute minimally to skin cancer risk in ID. These differences underscore the care and personalized approach necessary in biologic selection for patients with ID.
Le texte complet de cet article est disponible en PDF.Key words : biologic therapy, cutaneous malignancy, inflammatory bowel disease, Janus kinase inhibitors, psoriasis, rheumatoid arthritis
Abbreviations used : ARI, BCC, IBD, ID, IL, ILi, JAKi, MM, NMSC, PSM, RA, SCC, TNF, TNFi
Plan
| Funding sources: This article has no funding source. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: Data accessible via TriNetX is presented in aggregate form and only contains anonymized data as per the deidentification standard defined by the US Health Insurance Portability and Accountability Act (HIPAA) in section §164,514(a). Given this study used only deidentified data and did not involve individually identifiable patient data, this study was exempt from Institutional Review Board Approval. |
|
| Reprint requests: Kyle C. Lauck, MD. |
Vol 93 - N° 3
P. 724-732 - septembre 2025 Retour au numéro
Article précédent
- The impact of lifestyle factors on cardiometabolic comorbidities and mortality of psoriatic diseases: A multistate model analysis
- Yi Xiao, Songchun Yang, Yang Zhang, Yixuan Tong, Danrong Jing, Yinli Zhou, Hui Xiao, Yehong Kuang, Minxue Shen, Xiang Chen
- National opioid prescription decline across outpatient specialty surgeries: A claims database study
- Surya A. Veerabagu, Shannon T. Nugent, Zhi Geng, Arianna F. Yanes, John P. Fischer, Robert Kovell, Andrew F. Kuntz, Karthik Rajasekaran, Brian L. VanderBeek, Christopher J. Miller, Jeremy R. Etzkorn, Joseph F. Sobanko, H. William Higgins, Joanna Walker, Junqian Zhang, Cerrene N. Giordano
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?